Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tempest Therapeutics Inc
(NQ:
TPST
)
3.245
+0.035 (+1.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tempest Therapeutics Inc
< Previous
1
2
Next >
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
May 25, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 19, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Therapeutics (NASDAQ: TPST) Reports Strong Early Results From Phase 1b/2 Study of TPST-1120 in Hepatocellular Carcinoma
April 28, 2023
Tempest Therapeutics, Inc. (NASDAQ: TPST) is engaged as a clinical-stage oncology company, which is focused on the research and development
Via
Spotlight Growth
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
April 28, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
April 27, 2023
Webcast Conference Call Friday, April 28, 2023, at 8:30 a.m. ET
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
April 26, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
April 17, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Year End 2022 Financial Results and Provides Business Update
March 22, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting
March 15, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
March 14, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer
November 10, 2022
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting
November 02, 2022
TPST-1495 also will be featured in a separate presentation
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
October 06, 2022
From
Tempest Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.